HER2 overexpression is frequently associated with tumor metastasis and poor prognosis of breast cancer. More evidence indicates that HER3 is involved in HER2-resistant therapies. Combination treatments with two or more different monoclonal antibodies are a promising strategy to overcome resistance to HER2 therapies. We presented a novel fully human HER2-targeted monoclonal antibody, GB235, screened from a phage-display library against the HER2 antigen. GB235 in combination with Trastuzumab overcomes resistance in HER2-positive tumors and results in more sustained inhibition of tumor growth over time. The competition binding assay showed that the epitopes of GB235 do not overlap with those of Pertuzumab and Trastuzumab on HER2. Further HER2 mutagenesis results revealed that the binding epitopes of GB235 were located in the domain III of HER2. The mechanism of action of GB235 in blocking HER2-driven tumors is different from the mechanisms of Trastuzumab or Pertuzumab. GB235 does not affect the heterodimerization of HER2 and HER3, whereas the GB235 combined treatment with Trastuzumab significantly inhibited heregulin-induced HER3 phosphorylation and downstream signaling. Moreover, GB235 in combination with Trastuzumab reversed the resistance to heregulin-induced proliferation in HER2-overexpressing cancer cell lines. GB235 combined with Trastuzumab treatment in xenograft models resulted in improved antitumor activity. Complete tumor suppression was observed in the HER2-positive NCI-N87 xenograft model treated with the combination treatment with GB235 and Trastuzumab. In a Trastuzumab-resistant patient-derived tumor xenograft model GA0060, GB235 plus Trastuzumab reversed the resistance to Trastuzumab monotherapy. Because GB235 showed a different working mechanism with Pertuzumab and Trastuzumab, these agents can be considered complementary therapy against HER2 overexpression tumors.
HER2, also known as ErbB2, is a member of the HER receptor family, which also consists of EGFR (ErbB1), HER3 (ErbB3), and HER4 (ErbB4) receptors 1 . Overexpression of HER2 is considered a biomarker of malignant tumors with a poor prognosis and is presented in roughly 20~30% of breast cancer patients 2 . HER2 is also overexpressed in approximately 20% of gastroesophageal junction and gastric cancers with a poor prognosis 3 . Trastuzumab is a humanized anti-HER2 antibody and it is the first HER2-targeted therapeutic monoclonal antibody approved by the United States Food and Drug Administration (FDA) in 1998 for the therapy of metastatic HER2-positive breast cancer and in 2010 for the therapy of HER2-positive metastatic gastroesophageal junction and gastric cancer 4, 5 . Trastuzumab inhibits HER2 phosphorylation and consequently inhibits downstream signaling pathways 6 . More and more studies indicate that Trastuzumab inhibits ligand-independent HER3/HER2 interactions rather than blocking HER2 signaling 7 . However, not all patients with HER2 overexpression benefit from Trastuzumab therapy because of the initial or acquired resistance 8 . The precise mechanism of resistance to Trastuzumab is still unclear. More evidence indicates that the HER2-HER3 heterodimer 9 and its consequent downstream signaling play a crucial role in the tumor resistance and metastasis of HER2-positive cancer 10 . Many metastatic HER2-amplified cancers that either do not respond to, or are eventually resistant to Trastuzumab often recover the phospho-HER3 and PI3K-Akt-mTOR downstream signaling 11 .
Pertuzumab, a recombinant humanized monoclonal anti-HER2 antibody, sterically blocks HER2 heterodimerization with other HER receptors, especially HER3, and was approved by the FDA in 2012 for breast cancer therapy 12 . Pertuzumab and Trastuzumab bind to distinguishing epitopes on HER2, and the combination treatment inhibits HER2/HER3 signaling more effectively 13 . Trastuzumab combined with Pertuzumab and docetaxel was approved as a first-line therapy for HER2-positive metastatic breast cancer 14 . HER2-targeted bispecific antibodies in clinical development have demonstrated significant antitumor activity for the Trastuzumab-resistant malignant cancers in preclinical studies 15, 16 . MM-111, a bispecific antibody that specifically targets the HER2/ HER3 heterodimer, blocks heregulin binding and inhibits downstream signaling pathways. Trastuzumab alone had no effect on heregulin-induced paclitaxel resistance, whereas MM-111 in combination with Trastuzumab displayed significantly greater activity than either agent alone 17 . Ertumaxomab, a bispecific anti-CD3 × anti-HER2 antibody, targets HER2 on cancer cells and CD3 on T cells simultaneously. The trifunctional bispecific antibody can evoke immune immunocytotoxicity towards HER2-overexpressing cancer cells and exhibited antitumor activity 18 . Despite remarkable improvement in HER2-targeted therapy, a large number of patients face the risk of recurrence. Therefore, efforts in developing more efficient HER2 inhibitors to increase overall survival rates are necessary.
Here, we describe the characteristics and effects of a fully human antibody, GB235, binding to domain III of HER2 and recognizing different epitopes on HER2 than the ones recognized by Trastuzumab or Pertuzumab. The combination treatment of GB235 and Trastuzumab reversed the resistance to heregulin-driven proliferation in BT-474 and NCI-N87 HER2-overexpressing tumor cells. GB235 in combination with Trastuzumab demonstrated significant tumor growth inhibition in the NCI-N87 HER2-overexpressing xenograft model. Tumor growth was significantly inhibited by combined treatment with GB235 and Trastuzumab in a Trastuzumab-resistant patient-derived tumor xenograft (PDX) GA0060 compared to Trastuzumab alone. Therefore, GB235 in combination with Trastuzumab might be a potential therapy against HER2-positive tumors.
Results
Characterization of the novel anti-HER2 antibody. To identify a HER2 therapeutic antibody, we screened HER2-targeted scFvs using phage display technology against the human HER2 extracellular domain (HER2 ECD) antigen. The full IgG1 molecules were generated from the top twenty scFv colonies based on their affinity ranking to HER2 ECD. The superior candidate antibody showing the best inhibition against the heregulin-induced phosphorylation of HER3 was designated as GB235. The binding activity of GB235 for the antigen was evaluated in the recombinant human HER2 ECD proteins or HER2-overexpressing BT-474 cells. The binding specificity of GB235 to soluble human HER2 receptor was determined by an ELISA. The results showed that GB235 specifically bound to human HER2 ECD in a concentration-dependent manner, without binding to other EGFR family receptors (Fig. 1A) . The cell binding assay was investigated with flow cytometry, the GB235 specifically bound to BT-474 cells, which is consistent with the result of Trastuzumab and Pertuzumab (Fig. 1B) . The competition of binding activity was performed by an ELISA. The data demonstrated that GB235 does not compete with biotinylated Trastuzumab (Fig. 1C ) or biotinylated Pertuzumab ( Fig. 1D ), suggesting that GB235 does not bind to the same epitopes recognized by Trastuzumab or Pertuzumab on human HER2.
The affinity of GB235 for its antigen was evaluated by surface plasmon resonance. The kinetic parameters of the Biacore X 100 system gave similar K D values for human HER2 and cynomolgus HER2 ( Table 1 ). The dissociation coefficient (K D ) for human and cynomolgus HER2 was 1.69 nM and 2.18 nM, respectively. Antiproliferative effects of GB235 and HER2 family status. To additionally evaluate whether HER family status conveys sensitivity to HER2 neutralizing antibody GB235, we studied the HER2, HER3 levels and downstream signal activity of a panel of cancer cell lines. As shown in the Fig. 2A , the amount of HER2 was overexpressed in NCI-N87, BT-474, KPL-4 cells and moderately expressed in JIMT-1 and MDA-MB-175-VII cells, but was significantly lower in MCF7 cells. HER2 was heavily tyrosine phosphorylated in NCI-N87, BT-474 and KPL-4 cells. Although JIMT-1 moderately expressed HER2, we could detect only very low levels of P-HER2, which is consistent with a previous report 19 . Most of the cancer cell lines analyzed also expressed elevated levels of HER3. The constitutive expression of P-HER3 levels were higher in examined cancer cell lines, except in JIMT-1 and MCF7 cells. Total Akt and Erk1/2 proteins were expressed in all of the examined cell lines at various levels. The levels of P-Akt were higher in NCI-N87, BT-474 and JIMT-1 cells, but were lower in KPL-4 cells. The Erk1/2 pathway was more active in NCI-N87, JIMT-1 and MDA-MB-175-VII cells compared with that of BT-474, KPL-4 and MCF7 cells.
We further investigate the activation of HER3-HER2 signaling and its potential role in mediating resistance to Trastuzumab monotherapy. Previous studies indicate that the growth of MDA-MB-175-VII cells is dependent on autocrine growth factor of γ-heregulin through the HER3-HER2 signaling 20 . The combination of Pertuzumab with Trastuzumab-DM1 showed enhanced antiproliferative activity on MDA-MB-175-VII cells compared with either drug alone 21 . We found that either Trastuzumab or GB235 showed a partial antiproliferative activity against MDA-MB-175-VII cells, whereas the GB235 combined with Trastuzumab showed enhanced antiproliferative activity with a greater extent than each agent alone (p < 0.001) ( Fig. 2B ).
GB235 retains efficacy in the presence of heregulin-α in BT-474 cancer cells with acquired resistance to Trastuzumab.
To examine the efficacy of GB235 in combined treatment with Trastuzumab in vitro, we analyzed cell growth inhibition against heregulin-α-induced proliferation in HER2-overexpressing BT-474 cells 22 . The induced cell proliferation by heregulin-α in BT-474 cells was not inhibited by Trastuzumab treatment alone, while the combination treatment with GB235 and Trastuzumab inhibited heregulin-α-induced cell proliferation significantly (p < 0.001) ( Fig. 3A) . In contrast, no combination efficacy was observed in BT-474 cells treated in the absence of heregulin-α (data not shown).
To explore whether GB235 was able to inhibit heregulin-α-mediated HER3 activation and downstream signaling, BT-474 cells were treated with GB235 alone or in combination with Trastuzumab followed by exposure to heregulin-α. Treatment with GB235 or Trastuzumab alone to some extent inhibited the phosphorylation of HER3 and downstream signaling effectors of Erk1/2, only the combination treatment of GB235 and Trastuzumab resulted in completely attenuation of HER3 phosphorylation and downstream signaling of Erk1/2 (Fig. 3B ).
The reverse effect of GB235 in combination treatment with Trastuzumab in NCI-N87 cancer cells.
The antiproliferative activity of GB235 was examined in Trastuzumab-resistant gastric cancer cells in the presence of heregulin-α. HER2-overexpressing NCI-N87 gastric cancer cells are resistant to Trastuzumab monotherapy in vitro and in vivo 23 . Under heregulin-α-induced conditions, Trastuzumab alone showed a minor proliferation inhibition in the NCI-N87 cells. However, GB235 combined with Trastuzumab treatment displayed superior in vitro proliferation inhibitory activity compared with either of the antibody (p < 0.001) ( Fig. 4A ).
Next, we studied the inhibitory effects of GB235 or Trastuzumab alone, or the two antibodies in combination, on HER3 signaling activation in NCI-N87 cells. Upon heregulin-α stimulation, the phosphorylation of HER3 and downstream signaling mediators of Akt and Erk1/2 were assessed after the treatment with the antibodies in NCI-N87 cells. The results indicated that the GB235 or Trastuzumab alone had a partial effect on phosphorylation of HER3, Akt and Erk1/2, whereas GB235 in combination with Trastuzumab significantly decreased P-HER3, P-Akt and P-Erk1/2 (Fig. 4B ). The heterodimer of HER2/HER3 and downstream signaling play a pivotal role in tumorigenesis of NCI-N87 cells 24 . www.nature.com/scientificreports www.nature.com/scientificreports/ Heterodimerization inhibition assay and antibody-dependent cell-mediated cytotoxicity assay. The next aim of this study was to explore whether GB235 binding to HER2 ECD prevents the heterodimerization of HER2/HER3. U2OS (HER2-HER3) used in this study is a commercialized engineering cell line (DiscoverX, Fremont, USA), which stably expresses the extracellular domains of the HER2 receptor fused to the ProLink and HER3 fused to EA. The high signal to noise ratio makes the assay applicable to the detection of ligand-induced dimerization of HER2-HER3 receptors in the therapeutic neutralizing antibody studies 25 . As shown in Fig. 5A , the dose-response curve of Pertuzumab showed an inhibitory effect of heterodimerization induced by heregulin-1-β1. However, neither GB235 nor Trastuzumab directly inhibited the heterodimerization of HER2 and HER3. JIMT-1, derived from a breast cancer patient shows HER2 amplification and resistance to Trastuzumab monotherapy. In previous publications, Trastuzumab evoked antibody-dependent cell-mediated cytotoxicity (ADCC) on JIMT-1 cancer cells with dose-dependent cell death reaching 70 to 85% killing 26 . The ADCC activity induced by Trastuzumab was equally strong against JIMT-1or SKBR-3 cancer cells 27 . The JIMT-1 cells were used in our study to determine the antibody-dependent cell-mediated cytotoxicity. In contrast with Trastuzumab, GB235 had no ADCC effect on the JIMT-1 target cells ( Fig. 5B ).
GB235 targeted epitopes located in the domain III of HER2. To explore the mechanism by which GB235 inhibits HER2/HER3 signaling, efforts were made to identify the epitopes of GB235 on human HER2. HER2 ECD is composed of four domains (I, II, III and IV), associated with flexible regions. The truncated mutants of HER2 ECD d I , HER2 ECD d I-1/2II and HER2 ECD d I-1/2III lost binding activity to GB235. In contrast, the HER2 ECD d I-III showed reactivity toward GB235 (Fig. 6A ). Furthermore, the binding ability of the chimeric proteins of HER2 and HER3 to GB235 was evaluated. The result showed that HER2 I-III -HER3 IV was sufficient to mimic full-length human HER2 ECD d I-IV in the association with GB235. The HER3 I-III -HER2 IV was unable to bind to GB235 (Fig. 6B ). The species cross-reactivity of GB235 was determined by assessing the binding activity GB235 combined with Trastuzumab effectively inhibits tumor growth in xenograft models. The ability of the GB235 to block cell signaling and suppress cell proliferation in vitro supported the analysis of its therapeutic efficacy in vivo. We investigated the in vivo tumor growth activity of GB235 in combination with Trastuzumab in breast cancer and gastric cancer cells. KPL-4 xenograft tumors (Breast cancer) were strongly positive for HER2 staining 28 . Combination treatment with Trastuzumab and Pertuzumab dramatically enhanced the antitumor effect compared with each agent alone in KPL-4 xenograft model 29 . As shown in Fig. 7A , the administration of Trastuzumab alone (30 mg/kg) in mice bearing KPL-4 breast cancer xenograft induced significant tumor growth inhibition, while the GB235 alone (30 mg/kg) had no effect on the tumor growth. However, the anticancer activity of GB235 in combination with Trastuzumab in KPL-4 xenograft was significantly higher than Trastuzumab as a single agent (p < 0.05). Consistent with the results showing that the addition of GB235 to Trastuzumab is more effective at suppressing cancer cell proliferation in vitro, the combination of GB235 and Trastuzumab is also trended toward enhanced tumor growth inhibition in vivo.
Next, to evaluate whether combined GB235 and Trastuzumab could be an effective therapeutic strategy to overcome Trastuzumab resistance in vivo, we assessed the efficacy of GB235 and Trastuzumab in two other www.nature.com/scientificreports www.nature.com/scientificreports/ Trastuzumab-resistant human gastric cancer xenografts. For mice bearing of gastric patient-derived tumor xenograft, the PDX model GA0060 showed no response to Trastuzumab monotherapy 30 . In contrast, tumor growth was significantly suppressed in nude mice treated with combinatorial treatment with GB235 plus Trastuzumab in comparison to mice treated with Trastuzumab alone (Fig. 7B) (p < 0.001).
To further explore the potential of GB235 to overcome Trastuzumab resistance in vivo, we evaluated the antitumor activity in an additional Trastuzumab-resistant xenograft model. In the HER2-positive NCI-N87 xenograft, Trastuzumab monotherapy displayed poor ability in tumor growth inhibition 31 . To this end, we assess the efficacy of the combinational treatment of GB235 and Trastuzumab in the NCI-N87 xenograft model, as inhibition of HER3 in the HER2-positive gastric cancers exhibits a promising efficacy 32 . Notably, GB235 combined with Trastuzumab exhibited significant antitumor activity in NCI-N87 xenograft, whereas Trastuzumab alone displayed only partial effect (p < 0.001). Both dose ratios of GB235 and Trastuzumab (5 + 20 mg/kg, and 10 + 20 mg/ kg) significantly inhibited tumor growth by 84.1% and 83.6%, respectively (Fig. 8A,B) . A head-to-head comparison between the GB235 and Pertuzumab, combination treatment with GB235 and Trastuzumab inhibited tumor growth to a similar level as the treatment with the Pertuzumab plus Trastuzumab. Collectively, the results demonstrate that the addition of GB235 to Trastuzumab treatment sensitizes Trastuzumab-resistant cancer cells to Trastuzumab.
Discussion
Despite the fact that the prognosis of HER2 overexpressing metastatic breast cancer has been significantly improved with Trastuzumab therapy, more efficient therapies are necessary for relapsing or resistant cases. Heregulin rescues the cancer cells from the inhibitory effects of HER2 kinase antagonists through HER3 activation 33 . Moreover, the HER3 mediates resistance to the inhibitory effect of HER2, EGFR, and PI3K kinase inhibitors via HER3 up-regulation and activation 34 . Herein, we show that a fully human anti-HER2 antibody, GB235, in combination with Trastuzumab overcomes resistance to Trastuzumab monotherapy in vitro and in vivo. Either the autocrine or exogenous heregulin-induced cell proliferation was inhibited by the combined treatment of GB235 and Trastuzumab. The analysis of the HER2 and HER3 signaling pathway indicated that GB235 inhibits cancer cells by reducing the activation of the HER3 receptor and the downstream pathway effectors of Akt and Erk1/2. In line with the in vitro results, the combination therapy of GB235 and Trastuzumab demonstrated a strong and enduring antitumor effect in HER2-amplified xenograft tumors.
The mechanism of action of GB235 is different from that of Trastuzumab or Pertuzumab. Binding analysis of GB235 with HER2 mutants indicated that GB235 bound to nonoverlapping epitopes on domain III of HER2. Trastuzumab binds to domain IV of HER2 which inhibits the homodimerization between HER2 dimers 35 . Pertuzumab binds to domain II of HER2 and interferes with the heterodimerization between HER2 and the other HER family receptors 36 . Further studies were performed to improve the understanding of the mechanism Domain III of HER2 was reported to be involved in the function of HER2 and HER3 interaction 37 . Deletion of the key region (451-466) in domain III of HER2 ECD suppressed the transactivation of receptors and disrupted the constitutive conformation in the dimerization loop, which may lead to the trafficking behavior of intracellular kinase 38 . The asymmetric dimers between intracellular kinases of HER2/HER3 participate in the activation of signaling, as the kinase domain of HER3 serves as an allosteric activator of HER2 kinase 39, 40 . Conformation changes were detected in the HER2 activation loop during dimerization interactions with HER3, which were stabilized each other in the heterodimer 41, 42 . More reports have indicated that Trastuzumab disrupts noncanonical HER2-HER3 interactions that result in HER3 inactivation 43 . We hypothesize that GB235, once bound to domain III of HER2 ECD, locks the HER2 ECD into an inactive conformation. The combination of GB235 and Trastuzumab is more likely to influence the rearrangement of HER2/HER3, potentially augmenting the steric hindrance effect on the activation of the intracellular kinase.
In summary, we reported a novel fully human monoclonal antibody against HER2, GB235, which bound to domain III of HER2 ECD and displayed potential efficacy inhibiting HER3-mediated signaling in heregulin-induced Trastuzumab resistant cancer cells. This combined therapy of the two antibodies demonstrated superior antitumor effect in the relevant xenograft mouse models than Trastuzumab alone. GB235 in combination with Trastuzumab presents a novel approach for overcoming Trastuzumab-resistant breast and gastric cancers. The unique potential of GB235 provides an alternative or complementary therapeutic strategy to the standard of care for HER2-positive cancers.
Materials and Methods
Antibodies and reagents. Trastuzumab and Pertuzumab were purchased from Roche Pharmaceutical Ltd.
GB221 was developed as a potential Trastuzumab biosimilar, and is currently in Phase III clinical trial (NMPA Clinical approval number 2013L01513). The extensive side-by-side analysis of GB221 and Trastuzumab showed highly similar physicochemical properties and functional characterization. Both GB221 and Trastuzumab used in this report are collectively referred to as Trastuzumab. IgG1 isotype control was obtained from Crown Bioscience Inc. (Taicang, China). Heregulin-α and heregulin-1-β1 were purchased from R&D Systems Inc. (Minneapolis, USA). The PathHunter assay kit was purchased from DiscoveRx (Fremont, USA). The P-HER3 (Y1289), HER3, P-HER2(Y1248), HER2, Akt, P-Akt (S473), Erk1/2, P-Erk1/2, GAPDH rabbit monoclonal antibodies and Radio Immunoprecipitation Assay buffer (RIPA) were purchased from Cell Signaling Technology Inc (Boston, USA). All antibodies were used according to the manufacturer's recommended antibody dilutions. Phosphotase inhibitor cocktail and nitrocellulose membrane were obtained from Merck (Darmstadt, Germany). Both CytoTox 96 ® Non-Radioactive Cytotoxicity Assay kits and CellTiter 96 ® Aqueous One Solution (MTS) Cell Proliferation Assay kits were purchased from Promega Corporation (Wisconsin, USA). Selection of a single-chain fragment variable specific for the human HER2 extracellular domain. A fully human single-chain fragment variable (scFv) phage display library containing 7 × 10 10 individual clones was used for the selection of lead-scFv clones. The phage clones with a high binding activity to human HER2 were selected with phage ELISA. ScFv phage suspension was added into 96-well immuno plates captured with recombinant human HER2 extracellular domain (ECD)-Fc fusion protein and thoroughly washed to remove the nonspecific phage absorption. With four rounds of panning, the phages were eluted with a low pH glycine elution buffer and neutralized with Tris-base and amplified through E. coli XL1-blue infection. The scFv phage clones expressed in the bacteria were then purified and characterized. Positive phage clones were analyzed to identify clones with unique DNA sequences.
Construction and expression of the recombinant full-length IgG1 antibody. The scFv antibod-
ies were converted to full-length IgG1 with an overlapping PCR and determined for their biologic activity. The full-length IgG1 heavy chain was obtained with an overlapping PCR method using the synthesized signal peptide, the variable region of the phage clone heavy chain and the constant region of the synthesized IgG1 heavy chain. The light chain was also obtained with the same strategy. The light and heavy chain of the full-length IgG1 was cloned into an expression vector and transfected into Chinese hamster ovary (CHO) cells with electroporation. Stable cell lines were obtained through incubation in the presence of G418. The recombinant antibody in the serum-free culture medium was purified through Protein G affinity chromatography.
Immunoassays. The binding ability of GB235 to receptors was determined by Enzyme Linked
Immunosorbent Assay (ELISA). Nunc Maxisorp 96-well (flat-bottom) plates were coated with 1 µg/mL of HER family receptors in Phosphate Buffer Saline overnight at 4 °C. Nonspecific binding of antibodies was blocked with 2% Bovine Serum Albumin (BSA) for an hour at room temperature and washed three times with Phosphate Buffer Saline/0.1% Tween-20 (1 × PBST). One hundred microliters of goat Anti-Human IgG Fc-fragment-specific conjugated with Horseradish Peroxidase (1:10000) was added to the 96-well plates and incubated for an hour at room temperature. After washing, the 3,3′,5,5′-Tetramethylbenzidine substrate (TMB) was added to develop color and the absorbance was measured at 450 nm using a SpectraMax M5 plate reader (Molecular Devices, San Jose, USA).
Competition of the binding ability assay was performed. Either biotinylated Trastuzumab or biotinylated Pertuzumab (10 ng/mL) was pre-incubated with GB235 for an hour at 37 °C before adding to the wells of ELISA plate pre-coated with HER2 ECD recombinant protein. After washing with PBST, 100 µL of Streptavidin-Horseradish Peroxidase was added to each well and incubated for an hour at room temperature. Finally, the absorbance of color development was read by SpectraMax M5 plate reader (Molecular Devices, San Jose, USA) at wavelength of 450 nm. The data analysis was performed by GraphPad Prism (GraphPad Software) using a nonlinear, variable slope model.
Binding to HER2 positive BT-474 cells. A total of 1 × 10 6 BT-474 cells were added with dilutions of GB235, incubated for an hour at 4 °C in 100 µL of Phosphate Buffer Saline/1% Fetal Bovine Serum (PBS/1% FBS). Either Pertuzumab or Trastuzumab was used as positive control. The BT-474 cells were washed three times in cold PBS/1% FBS buffer and incubated with Fluorescein-conjugated goat anti-human IgG-Fc secondary antibody (1/200 dilution) for 45 min at 4 °C in PBS/1% FBS buffer. The cells were washed with three times, and analyzed using a Beckman Coulter FC500 Cytometer (Beckman, Kraemer Boulevard, USA). A total of 1 × 10 4 cells was counted for each sample. The binding affinity was analyzed with GraphPad Prism (GraphPad Software).
Surface plasmon resonance analysis. For binding kinetic studies, the binding of GB235 to HER2 was determined by surface plasmon resonance using a Biacore X 100 (GE Healthcare, Chicago, USA). Carboxyl groups on the chip were activated by N-hydroxysuccinimide and N-ethyl-N-(dimethylaminopropyl) carbodiimide and deactivated with Ethanolamine. GB235 was immobilized on the surface of a sensor chip CM5 via an anti-human IgG Fc antibody using amine coupling. Either human HER2 ECD or monkey HER2 ECD in HBS-EP + solution (GE Healthcare, Chicago, USA) was injected at various concentrations (1.56∼200 nM) over the flow cell. The interaction was determined at a flow rate of 5 μL/min. Data analysis was conducted with a 1:1 Langmuir fit model using BIAevaluation software.
In vitro cell proliferation assays. The effect of GB235 on tumor cell viability was assessed with the CellTiter 96 ® Aqueous One Solution Cell Proliferation Assay kit (MTS). Cells were plated into 96-well plates (5000 cells per well for BT-474; 20000 cells per well for NCI-N87 and MDA-MB-175-VII cell lines) in complete medium and incubated overnight at 37 °C in a humidified atmosphere of 5% CO 2 . The cell culture medium was replaced by fresh cell medium with serial dilutions of GB235, Trastuzumab alone or in combination (ranging In vivo tumor studies. Xenograft models were established by inoculation of human cancer cell lines or patient-derived tumor tissue in immune-deficient mice. For the KPL-4 (breast cancer) xenograft study, 9 × 10 6 of KPL-4 cells were inoculated orthotopically into the right penultimate inguinal mammary fats pad of 6-week-old female NOD/SCID mice. For NCI-N87 (gastric carcinoma) and gastric tumor patient-derived xenograft GA0060 (gastric carcinoma) in vivo studies, 2 × 10 6 of NCI-N87 cells or 30 mm 3 of GA0060 tissue were inoculated into the right flank of 6-week-old female BALB/c nude mice. When tumors reached 100∼150 mm 3 , tumor-bearing mice were randomized into vehicle and treatment groups. Tumor-bearing mice were intraperitoneally administered GB235, Trastuzumab alone or in combination once a week (or twice a week), while vehicle group received PBS. Tumors were measured twice weekly using calipers and calculated using the following formula: Volume = Length × Width × Width/2. The relative tumor growth inhibition rate (TGI %) was calculated as follows: TGI % = (1 − T o / T c ) × 100 (where T o is the tumor volume change of the antibody-treated group, T c is the tumor volume change of the vehicle group). The procedures of KPL-4 animal study involving the care and use of animals are reviewed and approved by the Institutional Animal Care and Use Committee in GenScript Bio Co., Ltd. The NCI-N87 animal study protocols were approved by the Institutional Animal Care and Use Committee in Shanghai Model Organisms Center, Inc. The GA0060 xenograft model was carried out upon approval of the Institutional Animal Care and Use Committee of the Crown Bioscience Inc. All animal care was in accordance with institution guidelines.
Statistical analysis. The assays were repeated two or three times and the results are representative of independent experiments. All experiments were performed in accordance with relevant guidelines and regulations. Statistical analysis was performed using GraphPad Prism version 5.0 (GraphPad Software, USA). Data were analyzed with one-way ANOVA for in vitro studies. The differences of tumor growth between the groups were analyzed by two-way ANOVA for in vivo studies. The values were presented as the mean ± SEM. p < 0.05 was considered statistically significant.
